Diffuse Large B-Cell Lymphoma, Not Otherwise Specified — Variants & evidence

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

6 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–6 of 6 evidence items (6 on this page mapped to a descendant entity) · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CD79B MUTATION1
(diagnostic)	MCD Diffuse Large B-Cell Lymphoma	Diagnostic	E	Supports Positive	3	submitted	EID11822 This is one of the genetic features of this subgroup PMID 32289277 · Wright et al., 2020 · Open in CIViC	civic
EZH2 expression1
Tazemetostat	Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type	Predictive	C	Supports Sensitivity Response	1	accepted	EID11108 In this phase I study (clinical trial NCT03009344), one patient with germinal center B‐cell‐like (GCB) DLBCL and two with non-GCB DLBCL types were recruited to test the efficacy of EZH2 inhibitor-Taze… (full text at CIViC) PMID 33492746 · Munakata et al., 2021 · Open in CIViC	civic
GNAI2 mutation1
(oncogenic)	EZB Diffuse Large B-Cell Lymphoma	Oncogenic	E	Supports Oncogenicity	4	submitted	EID11943 The study identified recurrently mutated genes in DLBCL using whole genome sequencing. PMID 23699601 · Morin et al., 2013 · Open in CIViC	civic
PIM1 L2V1
Ibrutinib	Diffuse Large B-Cell Lymphoma Activated B-Cell Type	Predictive	D	Supports Resistance	3	accepted	EID9945 Foundation panel results of baseline tumour samples from 48 patients with diffuse large B cell lymphoma identified PIM1 mutations in 6 patient samples, 5 of which were the DLBCL-ABC subtype. Four out … (full text at CIViC) PMID 27904766 · Kuo et al., 2016 · Open in CIViC	civic
PIM1 P81S1
Ibrutinib	Diffuse Large B-Cell Lymphoma Activated B-Cell Type	Predictive	D	Supports Resistance	3	accepted	EID9946 Foundation panel results of baseline tumour samples from 48 patients with diffuse large B cell lymphoma identified PIM1 mutations in 6 patient samples, 5 of which were the DLBCL-ABC subtype. Four out … (full text at CIViC) PMID 27904766 · Kuo et al., 2016 · Open in CIViC	civic
PIM1 S97N1
Ibrutinib	Diffuse Large B-Cell Lymphoma Activated B-Cell Type	Predictive	D	Supports Resistance	3	accepted	EID9947 Foundation panel results of baseline tumour samples from 48 patients with diffuse large B cell lymphoma identified PIM1 mutations in 6 patient samples, 5 of which were the DLBCL-ABC subtype. Four out … (full text at CIViC) PMID 27904766 · Kuo et al., 2016 · Open in CIViC	civic

Data updated 23 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.